@moleculexyz.bsky.social
DeSci biopharma IP tokenization protocol.
Fund & shape early-stage research ideas at https://www.molecule.xyz/
Fund & shape early-stage research ideas at https://www.molecule.xyz/
Fox03 is a research project backed by @vitadao, developing a new RNA therapeutic that shifts the longevity-linked FOXO3 gene into its health-promoting form and targeting the tissue breakdown behind degenerative disc disease.
A precise, scalable route to drugs that extend healthspan - on Molecule ↓
A precise, scalable route to drugs that extend healthspan - on Molecule ↓
November 28, 2025 at 12:35 PM
Fox03 is a research project backed by @vitadao, developing a new RNA therapeutic that shifts the longevity-linked FOXO3 gene into its health-promoting form and targeting the tissue breakdown behind degenerative disc disease.
A precise, scalable route to drugs that extend healthspan - on Molecule ↓
A precise, scalable route to drugs that extend healthspan - on Molecule ↓
Relieva targets pain relief through a proprietary cannabinoid-terpene formulation engineered for consistent, replicable results.
A functional hemp therapeutic build from controlled chemistry -- now live on Molecule↓
A functional hemp therapeutic build from controlled chemistry -- now live on Molecule↓
November 26, 2025 at 12:26 AM
Relieva targets pain relief through a proprietary cannabinoid-terpene formulation engineered for consistent, replicable results.
A functional hemp therapeutic build from controlled chemistry -- now live on Molecule↓
A functional hemp therapeutic build from controlled chemistry -- now live on Molecule↓
Every part of the work moves transparently through Molecule Labs -- all linked directly onchain to the $GALE token page.
> the entire research cycle, shared openly.
> the entire research cycle, shared openly.
November 25, 2025 at 12:59 AM
Every part of the work moves transparently through Molecule Labs -- all linked directly onchain to the $GALE token page.
> the entire research cycle, shared openly.
> the entire research cycle, shared openly.
The next Alzheimer's breakthrough may come from shutting off one protein.
And 1,900+ people just backed the research to test it.
$GALE closed 14.2x oversubscribed, with $712K USDC committed, to support a new approach that targets Alzheimer’s at its root: chronic inflammation.↓
And 1,900+ people just backed the research to test it.
$GALE closed 14.2x oversubscribed, with $712K USDC committed, to support a new approach that targets Alzheimer’s at its root: chronic inflammation.↓
November 25, 2025 at 12:59 AM
The next Alzheimer's breakthrough may come from shutting off one protein.
And 1,900+ people just backed the research to test it.
$GALE closed 14.2x oversubscribed, with $712K USDC committed, to support a new approach that targets Alzheimer’s at its root: chronic inflammation.↓
And 1,900+ people just backed the research to test it.
$GALE closed 14.2x oversubscribed, with $712K USDC committed, to support a new approach that targets Alzheimer’s at its root: chronic inflammation.↓
Molecule Labs is evolving, piece-by-piece, line-by-line
This week, our product & engineering teams are sketching the outlines of 2026. DeSci applies blockchain -- this century’s most powerful invention --to science’s most broken systems
Let's put the devs to work
This week, our product & engineering teams are sketching the outlines of 2026. DeSci applies blockchain -- this century’s most powerful invention --to science’s most broken systems
Let's put the devs to work
November 24, 2025 at 3:43 PM
Molecule Labs is evolving, piece-by-piece, line-by-line
This week, our product & engineering teams are sketching the outlines of 2026. DeSci applies blockchain -- this century’s most powerful invention --to science’s most broken systems
Let's put the devs to work
This week, our product & engineering teams are sketching the outlines of 2026. DeSci applies blockchain -- this century’s most powerful invention --to science’s most broken systems
Let's put the devs to work
We've opened a talking slot for DeSci Abu Dhabi - apply to speak to the DeSci community, hosted at the @ClevelandClinic
During the same week as @f1, @SolanaConf, @binance Blockchain Week & @bitcoinmenaconf
🔗 below!
During the same week as @f1, @SolanaConf, @binance Blockchain Week & @bitcoinmenaconf
🔗 below!
November 24, 2025 at 1:29 PM
We've opened a talking slot for DeSci Abu Dhabi - apply to speak to the DeSci community, hosted at the @ClevelandClinic
During the same week as @f1, @SolanaConf, @binance Blockchain Week & @bitcoinmenaconf
🔗 below!
During the same week as @f1, @SolanaConf, @binance Blockchain Week & @bitcoinmenaconf
🔗 below!
connect with the community → @NEURONGale
track & trade the science → molecule.xyz/ipts/gale
track & trade the science → molecule.xyz/ipts/gale
November 21, 2025 at 11:51 AM
connect with the community → @NEURONGale
track & trade the science → molecule.xyz/ipts/gale
track & trade the science → molecule.xyz/ipts/gale
Using a highly specific galectin-3 inhibitor, the team will dose mice with Alzheimer’s, tracking:
→ biological changes over 4 weeks
→ brain tissue for inflammation, plaque, and Alzheimer’s markers
→ full data analysis + final report
→ a follow-on funding decision
→ biological changes over 4 weeks
→ brain tissue for inflammation, plaque, and Alzheimer’s markers
→ full data analysis + final report
→ a follow-on funding decision
November 21, 2025 at 11:51 AM
Using a highly specific galectin-3 inhibitor, the team will dose mice with Alzheimer’s, tracking:
→ biological changes over 4 weeks
→ brain tissue for inflammation, plaque, and Alzheimer’s markers
→ full data analysis + final report
→ a follow-on funding decision
→ biological changes over 4 weeks
→ brain tissue for inflammation, plaque, and Alzheimer’s markers
→ full data analysis + final report
→ a follow-on funding decision
NEURON GALE is now live and trading on Molecule -- the only platform where you can track Alzheimer’s research milestones transparently and directly onchain
🧵⤵️
🧵⤵️
November 21, 2025 at 11:50 AM
NEURON GALE is now live and trading on Molecule -- the only platform where you can track Alzheimer’s research milestones transparently and directly onchain
🧵⤵️
🧵⤵️
Across the desert, we’ll gather to explore the future of science - one day of deep talks, reflection, and community at DeSci Abu Dhabi.
Hosted at the @ClevelandClinic, a modern altar of medicine.
December 10. Sign up to attend. More details to follow.
luma.com/DeSciAbuDha...
Hosted at the @ClevelandClinic, a modern altar of medicine.
December 10. Sign up to attend. More details to follow.
luma.com/DeSciAbuDha...
November 20, 2025 at 9:50 AM
Across the desert, we’ll gather to explore the future of science - one day of deep talks, reflection, and community at DeSci Abu Dhabi.
Hosted at the @ClevelandClinic, a modern altar of medicine.
December 10. Sign up to attend. More details to follow.
luma.com/DeSciAbuDha...
Hosted at the @ClevelandClinic, a modern altar of medicine.
December 10. Sign up to attend. More details to follow.
luma.com/DeSciAbuDha...
The funding stack for science is being rebuilt.
Beyond VC and grants, a new model is forming -- where capital, incentives, and ownership move on open rails.
A shift from static institutions ➝ liquid networks of discovery ↓
Beyond VC and grants, a new model is forming -- where capital, incentives, and ownership move on open rails.
A shift from static institutions ➝ liquid networks of discovery ↓
November 14, 2025 at 12:03 AM
The funding stack for science is being rebuilt.
Beyond VC and grants, a new model is forming -- where capital, incentives, and ownership move on open rails.
A shift from static institutions ➝ liquid networks of discovery ↓
Beyond VC and grants, a new model is forming -- where capital, incentives, and ownership move on open rails.
A shift from static institutions ➝ liquid networks of discovery ↓
Latest updates:
> Manufacturer factory visit
> Early scoping underway for potential human trials
Every milestone, dataset, and research update streams through Molecule Labs and flows directly into VITARNA's token page.
> Manufacturer factory visit
> Early scoping underway for potential human trials
Every milestone, dataset, and research update streams through Molecule Labs and flows directly into VITARNA's token page.
November 13, 2025 at 5:57 PM
Latest updates:
> Manufacturer factory visit
> Early scoping underway for potential human trials
Every milestone, dataset, and research update streams through Molecule Labs and flows directly into VITARNA's token page.
> Manufacturer factory visit
> Early scoping underway for potential human trials
Every milestone, dataset, and research update streams through Molecule Labs and flows directly into VITARNA's token page.
The smallest errors in our genetic code can cause the biggest failures in our cells.
$VITARNA targets nonsense mutations, one of the root causes of aging and disease.
Backed by @vitadao, decentralized longevity science, live onchain. ↓
$VITARNA targets nonsense mutations, one of the root causes of aging and disease.
Backed by @vitadao, decentralized longevity science, live onchain. ↓
November 13, 2025 at 5:57 PM
The smallest errors in our genetic code can cause the biggest failures in our cells.
$VITARNA targets nonsense mutations, one of the root causes of aging and disease.
Backed by @vitadao, decentralized longevity science, live onchain. ↓
$VITARNA targets nonsense mutations, one of the root causes of aging and disease.
Backed by @vitadao, decentralized longevity science, live onchain. ↓
From our screener: @BeeARDai -- an AI-powered multi-agent system mapping the psychedelic frontier.
Backed by @psy_dao, BeeARD turns literature, data, and experimental results into a decentralized knowledge graph that learns continuously.
Backed by @psy_dao, BeeARD turns literature, data, and experimental results into a decentralized knowledge graph that learns continuously.
November 12, 2025 at 9:01 PM
From our screener: @BeeARDai -- an AI-powered multi-agent system mapping the psychedelic frontier.
Backed by @psy_dao, BeeARD turns literature, data, and experimental results into a decentralized knowledge graph that learns continuously.
Backed by @psy_dao, BeeARD turns literature, data, and experimental results into a decentralized knowledge graph that learns continuously.
The first human trials for reversing aging are coming.
Life Biosciences plans to clinically testing a therapy that targets aging by 2026.
Aging is becoming a testable target. The clock isn’t unstoppable anymore. ↓
Life Biosciences plans to clinically testing a therapy that targets aging by 2026.
Aging is becoming a testable target. The clock isn’t unstoppable anymore. ↓
November 11, 2025 at 2:58 PM
The first human trials for reversing aging are coming.
Life Biosciences plans to clinically testing a therapy that targets aging by 2026.
Aging is becoming a testable target. The clock isn’t unstoppable anymore. ↓
Life Biosciences plans to clinically testing a therapy that targets aging by 2026.
Aging is becoming a testable target. The clock isn’t unstoppable anymore. ↓
Today science sits in silos. Tomorrow it lives in markets.
November 9, 2025 at 2:59 AM
Today science sits in silos. Tomorrow it lives in markets.
From our screener: $AUBRAI -- the world's first BioAgent generating and owning onchain IP.
Trained on the mind of @aubreydegrey, powered by @Bioprotocol + Molecule's Proof of Invention rails.
Build for onchain science acceleration👇
Trained on the mind of @aubreydegrey, powered by @Bioprotocol + Molecule's Proof of Invention rails.
Build for onchain science acceleration👇
November 5, 2025 at 8:57 PM
From our screener: $AUBRAI -- the world's first BioAgent generating and owning onchain IP.
Trained on the mind of @aubreydegrey, powered by @Bioprotocol + Molecule's Proof of Invention rails.
Build for onchain science acceleration👇
Trained on the mind of @aubreydegrey, powered by @Bioprotocol + Molecule's Proof of Invention rails.
Build for onchain science acceleration👇
Science is still running on feudal infrastructure.
New systems are inevitable.
New systems are inevitable.
November 2, 2025 at 1:58 AM
Science is still running on feudal infrastructure.
New systems are inevitable.
New systems are inevitable.
Traditional science funding is in crisis.
Meanwhile, tokenized IP is accelerating.
Molecule connects breakthrough science with a breakthrough market.
Meanwhile, tokenized IP is accelerating.
Molecule connects breakthrough science with a breakthrough market.
October 30, 2025 at 11:03 PM
Traditional science funding is in crisis.
Meanwhile, tokenized IP is accelerating.
Molecule connects breakthrough science with a breakthrough market.
Meanwhile, tokenized IP is accelerating.
Molecule connects breakthrough science with a breakthrough market.
Last week, an AI model imagined a cancer treatment -- and got it right.
This week, DrugReflector finds useful compounds 17x faster than traditional research.
The lab is turning into a thinking system --
recursive, transparent, self-improving. 👇
This week, DrugReflector finds useful compounds 17x faster than traditional research.
The lab is turning into a thinking system --
recursive, transparent, self-improving. 👇
October 28, 2025 at 2:04 PM
Last week, an AI model imagined a cancer treatment -- and got it right.
This week, DrugReflector finds useful compounds 17x faster than traditional research.
The lab is turning into a thinking system --
recursive, transparent, self-improving. 👇
This week, DrugReflector finds useful compounds 17x faster than traditional research.
The lab is turning into a thinking system --
recursive, transparent, self-improving. 👇
We’re optimizing for safety, not discovery -- producing endless variations of the same drug.
@fedichev explains how Pharma's risk aversion is dangerous for innovation.
@fedichev explains how Pharma's risk aversion is dangerous for innovation.
October 27, 2025 at 3:28 PM
We’re optimizing for safety, not discovery -- producing endless variations of the same drug.
@fedichev explains how Pharma's risk aversion is dangerous for innovation.
@fedichev explains how Pharma's risk aversion is dangerous for innovation.
For a decade, US Supreme Court rulings pulled biotech inventions into "abstract ideas".
The new PERA (Patent Eligibility Restoration Act) could redraw the innovation landscape
> It redefines what's patentable across biotech, AI, and diagnostics -- potentially ending years of uncertainty.
The new PERA (Patent Eligibility Restoration Act) could redraw the innovation landscape
> It redefines what's patentable across biotech, AI, and diagnostics -- potentially ending years of uncertainty.
October 23, 2025 at 11:20 PM
For a decade, US Supreme Court rulings pulled biotech inventions into "abstract ideas".
The new PERA (Patent Eligibility Restoration Act) could redraw the innovation landscape
> It redefines what's patentable across biotech, AI, and diagnostics -- potentially ending years of uncertainty.
The new PERA (Patent Eligibility Restoration Act) could redraw the innovation landscape
> It redefines what's patentable across biotech, AI, and diagnostics -- potentially ending years of uncertainty.
The model predicted that a known cancer drug under specific immune context, could make “cold” tumors visible to the immune system.
> lab tests confirmed it: combining silmitasertib + low-dose interferon boosted immune visibility ~50%.
> lab tests confirmed it: combining silmitasertib + low-dose interferon boosted immune visibility ~50%.
October 21, 2025 at 2:01 PM
The model predicted that a known cancer drug under specific immune context, could make “cold” tumors visible to the immune system.
> lab tests confirmed it: combining silmitasertib + low-dose interferon boosted immune visibility ~50%.
> lab tests confirmed it: combining silmitasertib + low-dose interferon boosted immune visibility ~50%.
An AI model just made -- and experimentally proved -- a new cancer discovery.
Google & Yale’s Cell2Sentence-Scale (27B) generated a hypothesis that turned out to be correct in living cells.
Scientific singularity is already happening. 👇
Google & Yale’s Cell2Sentence-Scale (27B) generated a hypothesis that turned out to be correct in living cells.
Scientific singularity is already happening. 👇
October 21, 2025 at 2:01 PM
An AI model just made -- and experimentally proved -- a new cancer discovery.
Google & Yale’s Cell2Sentence-Scale (27B) generated a hypothesis that turned out to be correct in living cells.
Scientific singularity is already happening. 👇
Google & Yale’s Cell2Sentence-Scale (27B) generated a hypothesis that turned out to be correct in living cells.
Scientific singularity is already happening. 👇